Galena Biopharma Inc. (GALE)

5.72
0.00 (0.00)
NASDAQ : Health Technology
Prev Close 5.72
Open 5.72
Day Low/High 5.56 / 5.85
52 Wk Low/High 3.43 / 19.80
Volume 55.42K
Avg Volume 886.60K
Exchange NASDAQ
Shares Outstanding 45.71M
Market Cap 11.98M
EPS -2,128.20
P/E Ratio N/A
Div & Yield N.A. (N.A)
GALE March 27th Options Begin Trading

GALE March 27th Options Begin Trading

Investors in Galena Biopharma Inc saw new options begin trading today, for the March 27th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GALE options chain for the new March 27th contracts and identified the following put contract of particular interest.

Galena Biopharma (GALE) Is Weak On High Volume Today

Galena Biopharma (GALE) Is Weak On High Volume Today

Trade-Ideas LLC identified Galena Biopharma (GALE) as a weak on high relative volume candidate

GALE February 27th Options Begin Trading

GALE February 27th Options Begin Trading

Investors in Galena Biopharma Inc saw new options become available today, for the February 27th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GALE options chain for the new February 27th contracts and identified the following put contract of particular interest.

Galena Biopharma Provides 2015 Outlook

Galena Biopharma Provides 2015 Outlook

Company Anticipates Multiple Key Milestones Across Its Commercial and Clinical Portfolio

Biotech-Twitter 2014: A Look Back at the Biotech Year Through the Twitter Lens

Biotech-Twitter 2014: A Look Back at the Biotech Year Through the Twitter Lens

Another crazy and profitable year in biotech investing was captured 140 characters at a time.

Adam Feuerstein's 2014 Biotech Stock Report Card (No Grading on a Curve)

Adam Feuerstein's 2014 Biotech Stock Report Card (No Grading on a Curve)

Good calls: Vertex, InterMune, Chelsea, Galena, Exact Sciences. The bad calls: Avanir, Amarin, Exelixis and the bursting biotech stock bubble.

Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ...

Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ...

The CEOs of Aegerion, Dendron, CytRx, Galena, Repros, Northwest Bio and Retrophin deserve jeers for their performances this year, but who's the worst of the bunch?

Biotech Stock Mailbag: Aethlon Medical, Oxigene, Sarepta

Biotech Stock Mailbag: Aethlon Medical, Oxigene, Sarepta

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Galena, Shunned by Wall Street, Forced to Seek Pricey Vulture Financing

Galena, Shunned by Wall Street, Forced to Seek Pricey Vulture Financing

The scandal-ridden Galena, still under active SEC investigation, was unable to muster sufficient interest from institutional investors.